Beta cell mass in Type 1 diabetes mellitus and islet transplantation

1 型糖尿病和胰岛移植中的β细胞团

• 批准号: nhmrc : 427695
• 负责人: A/Pr David Laybutt
• 金额: $ 204.72万
• 依托单位: Garvan Institute of Medical Research
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Strategic Awards
• 财政年份: 2008
• 资助国家: 澳大利亚
• 起止时间: 2008-01-01 至 2012-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/beta-cell-mass-islet-transplantation/82416
• 关键词: Beta; cell; mass; Type; diabetes

This research program will examine the cellular and molecular mechanisms underlying the loss of Beta cell mass and function: During the pathogenesis of Type 1 Diabetes Mellitus (T1D); and Following islet transplantation. Though these processes have traditionally been considered to be purely immune-mediated, it is now clear that the response of the beta cell is critical to the final outcome of the auto-immune process and response to therapeutic interventions. Thus the complex interactions between the cellular and soluble constituents of the immune system, plus the effects of a deregulated metabolic milieu, are integrated at the beta cell. This in turn activates a series of complex transcriptional programs in the beta cell that together determine the beta cells ultimate functional status and survival. We will use knowledge gained from studying these processes to drive the development of novel therapeutic targets and strategies to improve the success of immune-based and transplantation-based therapies.

本研究项目将研究β细胞质量和功能丧失的细胞和分子机制：在1型糖尿病（T1D）的发病过程中；胰岛移植后。虽然这些过程传统上被认为是纯免疫介导的，但现在很清楚，β细胞的反应对自身免疫过程的最终结果和对治疗干预的反应至关重要。因此，免疫系统的细胞和可溶性成分之间的复杂相互作用，加上代谢环境的解除管制的影响，在β细胞中被整合。这反过来激活β细胞中一系列复杂的转录程序，共同决定β细胞的最终功能状态和存活。我们将利用从研究这些过程中获得的知识来推动新的治疗靶点和策略的发展，以提高基于免疫和移植的治疗方法的成功。